Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPASS: Tividenofusp Alfa vs Idursulfase in MPS II
NCT05371613Phase 3Active, not recruiting
- Sponsor
- Denali Therapeutics Inc.
- Start
- Jul 2022
- Primary completion
- Dec 2027
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of tividenofusp alfa in mucopolysaccharidosis type II (3 arms), sponsored by Denali Therapeutics Inc. Primary endpoints: Cerebrospinal fluid heparan sulfate concentration at 24 weeks and Vineland Adaptive Behavior Scale, Third Edition at 96 weeks. Started Jul 2022; status: active, not recruiting.
02
Drugs
tividenofusp alfa
03
Conditions
mucopolysaccharidosis type II
Beyond the preview
Go deeper on NCT05371613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05371613.